US › Healthcare

Tenaya Therapeutics Inc (TNYA)

US · Healthcare · Biotechnology

$0.67+2.20%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.1M

Net profit

$-43.4M

EPS

$-0.09

EPS estimate

$-0.08

Net margin

-3,909.3%

EPS came in at -0.09 against a street estimate of -0.08 — a miss of 12.5%.

Key statistics

Market cap

$143.5M

Forward P/E

0.0

P/B

2.07

Book value

$0.49

EPS (TTM)

$-0.51

52-week high

$2.35

52-week low

$0.53

50-day MA

$0.75

200-day MA

$0.79

Beta

2.78

Analyst view

Analysts rate Tenaya Therapeutics Inc a strong buy (9 buy, 0 hold, 0 sell out of 9) with an average price target of $3.20.

Shareholding

Insiders

0.44%

Institutions

48.87%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.78%
Millennium Management LLC	2.87%
Citadel Advisors Llc	2.04%
Kalehua Capital Management LLC	1.78%
Empery Asset Management, LP	1.72%
Renaissance Technologies Corp	1.66%
BlackRock Inc	1.65%
Marshall Wace Asset Management Ltd	1.21%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tenaya Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.